A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer

Trial Profile

A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Capecitabine (Primary) ; Celecoxib (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms ADAPT
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 May 2017 Status changed from suspended to discontinued as Funding ended.
    • 25 Mar 2016 Status changed from recruiting to suspended, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top